-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Centessa Pharmaceuticals, Raises Price Target to $62

Benzinga·12/10/2025 16:36:55
Listen to the news
Oppenheimer analyst Kostas Biliouris maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Outperform and raises the price target from $40 to $62.